J
John M. Zahradnik
Researcher at Sanofi Pasteur
Publications - 12
Citations - 631
John M. Zahradnik is an academic researcher from Sanofi Pasteur. The author has contributed to research in topics: Vaccination & Antigen. The author has an hindex of 11, co-authored 12 publications receiving 621 citations.
Papers
More filters
Journal ArticleDOI
A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects.
Klara Berencsi,Zsofia Gyulai,Eva Gonczol,Steve Pincus,William I. Cox,Susan Michelson,Laszlo Kari,Claude Meric,Michel Cadoz,John M. Zahradnik,Stuart E. Starr,Stanley A. Plotkin +11 more
TL;DR: Canarypox-CMV pp65 is the first recombinant vaccine to elicit CMV-specific CTL responses, which suggests the potential usefulness of this approach in preventing disease caused by CMV.
Journal ArticleDOI
A Canarypox Vector Expressing Cytomegalovirus (CMV) Glycoprotein B Primes for Antibody Responses to a Live Attenuated CMV Vaccine (Towne)
Stuart P. Adler,Stanley A. Plotkin,Eva Gonczol,Michel Cadoz,Claude Meric,Jian Ben Wang,Pierre Dellamonica,Al M. Best,John M. Zahradnik,Steve Pincus,Klara Berencsi,William I. Cox,Zsofia Gyulai +12 more
TL;DR: It is demonstrated that ALVAC-CMV(gB) primes the immune system and a combined-vaccine strategy to induce potentially protective levels of neutralizing antibodies is suggested.
Journal ArticleDOI
Effect of Previous or Simultaneous Immunization with Canarypox Expressing Cytomegalovirus (CMV) Glycoprotein B (gB) on Response to Subunit gB Vaccine plus MF59 in Healthy CMV-Seronegative Adults
David I. Bernstein,Mark R. Schleiss,Klara Berencsi,Eva Gonczol,Michelle Dickey,Phil Khoury,Michel Cadoz,Claude Meric,John M. Zahradnik,Anne Marie Duliege,Stanley A. Plotkin +10 more
TL;DR: All 3 vaccine regimens induced high-titer antibody and lymphoproliferative responses, but no benefit for priming or simultaneous vaccination was detected.
Journal ArticleDOI
Antibody Response of Adults to an Aluminum Hydroxide-Adsorbed Neisseria meningitidis Serotype 2b Protein-Group B Polysaccharide Vaccine
TL;DR: A group B Neisseria meningitidis serotype protein vaccine was studied clinically in adults and induction of bactericidal antibodies has been shown to be a major predictor of protection against meningococcal disease.
Journal ArticleDOI
Class-Specific Human Bactericidal Antibodies to Capsular and Noncapsular Surface Antigens of Neisseria meningitidis
TL;DR: Bactericidal and enzyme-linked immunosorbent assays were used to determine the immunoglobulin classes responsible for group- and type-specific immunity to Neisseria mening itidis among healthy, unvaccinated individuals and persons who received group-B N meningitidis polysaccharide-serotype-2 protein vaccine.